Appili Therapeutics Inc. (OTCMKTS:APLIF) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 15,700 shares, a growth of 190.7% from the December 15th total of 5,400 shares. Based on an average trading volume of 83,100 shares, the days-to-cover ratio is currently 0.2 days.
APLIF stock opened at $0.88 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.74 and a quick ratio of 13.74. The company has a 50-day moving average price of $0.95. The company has a market capitalization of $55.07 million and a P/E ratio of -6.77. Appili Therapeutics has a 1-year low of $0.57 and a 1-year high of $1.37.
Appili Therapeutics (OTCMKTS:APLIF) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.03) earnings per share for the quarter.
Appili Therapeutics Company Profile
Appili Therapeutics Inc, a biopharmaceutical company, acquires, develops, and commercializes novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1501, a taste-masked oral liquid suspension formulation of an antibiotic, metronidazole; ATI-1503 that develops a class of gram-negative targeting antibiotics; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis.
Featured Story: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.